Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Settles 14 Stent Patent Suits With J&J For $716 Million

This article was originally published in The Gray Sheet

Executive Summary

Long-time stent rivals Boston Scientific and Johnson & Johnson signed a partial patent détente Sept. 29, but the companies are not finished battling over intellectual property for the profitable devices

You may also be interested in...



J&J/Cordis v. Boston Scientific

Johnson & Johnson's Cordis unit plans to appeal a Jan. 20 ruling in Delaware federal court that found four of its drug-eluting stent patents to be invalid. The so-called Wright/Falotico patents relate to drug and polymer coatings for stents and are at issue in a 2007 suit brought by J&J/Cordis claiming infringement by Boston Scientific's Promus everolimus-eluting stent system. J&J notes that the ruling "is not expected to have any effect on Cordis' other litigation against the Promus product based on its Morris, Llanos and Fischell patent families." Last fall, Boston Scientific settled 14 other stent patent suits with J&J by paying $716 million. "We continue to attempt to resolve remaining outstanding matters with J&J," said Boston Scientific CEO Ray Elliott on Jan. 20 (1"The Gray Sheet" Oct. 5, 2009)

J&J/Cordis v. Boston Scientific

Johnson & Johnson's Cordis unit plans to appeal a Jan. 20 ruling in Delaware federal court that found four of its drug-eluting stent patents to be invalid. The so-called Wright/Falotico patents relate to drug and polymer coatings for stents and are at issue in a 2007 suit brought by J&J/Cordis claiming infringement by Boston Scientific's Promus everolimus-eluting stent system. J&J notes that the ruling "is not expected to have any effect on Cordis' other litigation against the Promus product based on its Morris, Llanos and Fischell patent families." Last fall, Boston Scientific settled 14 other stent patent suits with J&J by paying $716 million. "We continue to attempt to resolve remaining outstanding matters with J&J," said Boston Scientific CEO Ray Elliott on Jan. 20 (1"The Gray Sheet" Oct. 5, 2009)

Medtronic, Abbott Settle Longstanding Stent IP Battles For $400 Mil.

Medtronic will pay Abbott Laboratories $400 million to resolve a costly series of global stent patent battles that have dragged on since the '90s and in some cases limited the companies' ability to commercialize in certain markets

Related Content

Topics

UsernamePublicRestriction

Register

MT027983

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel